COEP

Coeptis Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 2

Price Hits New Low

Price Hits 52-week low

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About COEP

Coeptis Therapeutics Holdings, Inc.

A biopharmaceutical company that developing innovative cell therapy platforms for cancer

Industry

Life Science Tools and Services

Established Date

Invalid Date

Listing Date

12/17/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.coeptistx.com

Security Type

Common stock

Office address

105 Bradford Rd, Suite 420, Wexford, Pennsylvania, 15090

Business

Introduction

Coeptis Therapeutics Holdings, Inc., originally incorporated in Colorado in 1996 as Nelx Marketing Inc., later changed its name to Mind 2 Market, Inc. (1996) and then to Health Partnership, Inc. (2005), It was then renamed Naerodynamics, Inc. (2008). In January 2020, Coeptis moved to Delaware and changed its then corporate name to NDYN Merger Corp. In February 2020, NDYN Merger Corp. promulgated a holding company reorganization under Section 251 (g) of the DGCL and changed the company name to Vinings Holdings, Inc. Effective July 12, 2021, the company name will be changed to "Coeptis Therapeutics, Inc." Coeptis' current business model is designed around further developing its existing product portfolio. Coeptis is constantly exploring partnership opportunities with companies at different stages of development with new therapies or with technologies that improve the way they deliver medicines to patients. Coeptis seeks optimal strategic relationships that can include in-licensing agreements, out-of-licensing agreements, co-development arrangements, and other strategic partnerships in new and exciting therapeutic areas such as autoimmune diseases and oncology.

Company Financials

EPS

COEP has released its 2023 Q3 earnings. EPS was reported at -0.23, versus the expected -0.01, missing expectations. The chart below visualizes how COEP has performed over recent quarters, highlighting trends in earnings surprises.